Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
atazanavir (Reyataz®)
Reference No. 29
Publication date:
21/01/2009
Appraisal information
atazanavir (Reyataz®) capsule
Company:
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF category:
Infections
NMG meeting date:
12/11/2008
AWMSG meeting date:
10/12/2008
Submission Type:
Full Submission
Status:
Recommended
Advice No:
2308
Ratification by Welsh Government:
19/01/2009
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Atazanavir (Reyataz®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-experienced patients, in accordance with British HIV Association (BHIVA) guidance. Atazanavir (Reyataz®) is not suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download
atazanavir (Reyataz) 29 FAR